Early experience with preclinical peri-operative cardiac xenograft dysfunction in a single program.
Peri-operative cardiac xenograft dysfunction (PCXD) was described by McGregor et al. to be a major barrier to the translation of heterotopic cardiac xenotransplantaton into the orthotopic position. It is characterized by graft dysfunction in the absence of rejection within 24-48 hours of transplantation. We describe our experience with PCXD at a single program. Orthotopic transplantation of genetically engineered pig hearts was performed in 6 healthy baboons. The immunosuppression regimen included induction by anti-CD20 mAb, Thymoglobulin, cobra venom factor and anti-CD40 mAb and maintenance with anti-CD40 mAb, MMF and tapering doses of steroids. Telemetry was used to asses graft function. Extracorporeal membrane oxygenation was used to support one recipient. A full human clinical transplant team was involved in these experiments and the procedure was performed by skilled transplant surgeons. A maximal survival of 40 hours was achieved in these experiments. The surgical procedures were uneventful and all hearts were weaned from cardiopulmonary bypass (CPB) without issue. Support with inotropes and vasopressors was generally required after separation from CPB. The cardiac xenografts performed well immediately, but within the first several hours required increasing support and ultimately suffered arrest despite maximal interventions. All hearts were explanted immediately; histology showed no signs of rejection. Despite excellent surgical technique, uneventful weaning from CPB, and adequate initial function, orthotopic cardiac xenografts slowly fail within 24-48 hours without evidence of rejection. Modification of preservation techniques and minimizing donor organ ischemic time may be able to ameliorate PCXD.